Tyrphostin B44, (+) enantiomer
Epidermal growth factor receptor (EGFR) kinase inhibitor (IC50 = 0.86 μM). Slightly less active than the (-) enantiomer (Cat. No. 0578).
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 308.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.24 mL||16.22 mL||32.43 mL|
|5 mM||0.65 mL||3.24 mL||6.49 mL|
|10 mM||0.32 mL||1.62 mL||3.24 mL|
|50 mM||0.06 mL||0.32 mL||0.65 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Gazit et al (1991) Tyrphostins. 2. Heterocyclic and α-substituted benzylidenemalononitrile tyrophostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J.Med.Chem. 34 1896 PMID: 1676428
If you know of a relevant reference for Tyrphostin B44, (+) enantiomer, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: EGFR kinase inhibitors inhibits Epidermal Growth Factor Receptors ErbB Her RTK Receptor Tyrosine Kinases RTKs (+)-TyrphostinB44 EGFR
Citations for Tyrphostin B44, (+) enantiomer
Citations are publications that use Tocris products.
Currently there are no citations for Tyrphostin B44, (+) enantiomer. Do you know of a great paper that uses Tyrphostin B44, (+) enantiomer from Tocris? If so please let us know.
Literature in this Area
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.